Diabetes, Heart and Cardiovascular Diseases News Chronicle Diabetes, Cardiovascular and Heart Diseases. Article 316
Published on March 30, 2018 at 05:30 PM GMT

FDA permits marketing of dermaPACE device to treat diabetic foot ulcers

Device for the treatment of venous, arterial, ischemic, diabetic foot, decubitus, pressure or bed sores ulcers.

High blood sugar or glucose levels (a condition known as type 2 diabetes T2D) damages small blood vessels and restricts blood supply through them to nerves. Nerves and nerve fibres will be damaged as blood rich with essential nutrients, glucose and oxygen could not be delivered to them. An individual affected with nerve damage will loose sensation in those areas. Nerves will become susceptible to infections and injury due to nerve damage, leading to ulcers development. Studies shows high blood sugar or glucose levels is the major cause of lower limb amputations.

Suwanee, Georgia, United States based Sanuwave Health, Inc. has developed dermaPACE device, a novel shock wave device for the treatment of acute and chronic wounds or ulcers. This device was developed using Sanuwave's proprietary and patented "Pulsed Acoustic Cellular Expression" (PACE) technology. This technology uses external high-energy acoustic shock waves (similar to sound waves) to stimulate the wound and to restore normal healing process of the body such as tissue repair and regeneration and growth of blood vessels.

This technology was being used for the past 30 years in medical treatments and procedures. The device was designed for the treatment of chronic, full-thickness diabetic foot ulcers, but not extending to bone level, lasting for more than 30 days. The device can treat ulcer areas of size not more than 16 cm2. The standard diabetic ulcer care should be used along with the dermaPACE device treatment. The device can treat wounds or ulcers such as

Clinical trial for 24 weeks duration was conducted among 336 diabetic foot ulcer patients at 39 centers. Prior to trial, participants were under usual ulcer treatment and they were either with well controlled or poorly controlled blood sugar or glucose levels. Patients were subjected to either with sham dermaPACE treatment plus usual care for wound treatment or active dermaPACE plus usual care for wound treatment. The trial results shows

There are minimal risks associated with dermaPACE device treatment. The common side effects observed with dermaPACE device treatment were

The CE marked dermaPACE device has got marketing permission on December 28, 2017 from the United States Food and Drug Administration.

If you like this article, please share it with a friend! Article address is (copy and past the code below):

Also related to this story
1. About Diabetic Shoes To Treat Neuropathy
2. Blood Vessel Function Benefits With Weight Lifting Exercises
3. Exercise protein cardiotrophin 1 (CT1) stimulates growth of blood vessels, helps growth of heart muscle & ventricle in a healthy way and improves ability of the heart to pump more blood
4. Diabetic foot ulcers (DFU) could be predicted with SmartMat ™ from Podimetrics
5. Permanent dysfunction of blood vessels with pregnancy preeclampsia condition in women
6. Poor sleeping habits in adults with type 2 diabetes was linked with high blood sugar levels, neuropathic pain and fatigue
7. Hyperglycemia & New AP39 Drug To Prevent Blood Vessel Complications Due To Hydrogen Sulfide (H2S)
8. Relief for chronic diabetic nerve pain or neuropathy by blocking HCN2 protein
9. Research On Healing Chronic Foot Wounds
10. Risks With Neuropathy
11. Study shows diabetic foot ulcer patient need a quick review as the the condition worsens quickly
12. Study To Treat Diabetic Foot Ulcers
13. Treatment For Diabetic Foot Ulcers
14. Treatment To Diabetic Neuropathy
15. Treatment With ReGenerCell For Diabetic Foot Ulcer
16. Tropical Gel Heals Wounds And Ulcers Fast



Sitemap 1   Sitemap 2   Sitemap 3   Sitemap 4


Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.

Published by Jammi Vasista, Chennai, India.
Email Jammi[no-space]Vasista1991[at]gmail[dot]com
Phone 91-944-578-3182.
Address Diabetes News Chronicle, No 40, Kaveri Street, Rajaji Nagar, Villivakkam, Chennai, India. Pin : 600049.